N E W S A R C H I V E
The Center has moved into the newly opened Marsico Hall at 125 Mason Farm Road, Chapel Hill, NC 27599-7363. More
Jian Jin to speak at the Medicinal Chemistry Gordon Research Conference, August 4-9, 2013, New London, NH. More information/registration
Stephen Frye to speak at Molecular Therapeutics of Cancer Research Conference, July 14-18, 2013, Boulder, CO. More information/registration
Stephen Frye to present at 36th Annual UNC Lineberger Comprehensive Cancer Center Symposium, April 25-26, 2012.
Stephen Frye to present in the Drug Discovery Centers section of the October 18, 2011 Baltimore conference
Drug Discovery in Academia - The New Paradigm for Drug Discovery
Bill Janzen and collaborator Cyrus Vaziri (lead PI) receive NIH grant targeting the TLS DNA Damage Tolerance Pathway for Cancer Therapy. Read More
Bill Janzen, postdoctoral fellow Samantha Pattenden, and bioengineering collaborator Paul Dayton receive R21 grant for "Cavitation Enhancement of Biospecimen processing for Improved DNA Fragmentation." This project will develop a technology that will maximize the quality and utility of samples (DNA) as well as improve assay speed and reduce cost, for downstream molecular analysis specifically for cancer biology.
NIH funds U19 Cooperative Program Project: Dr. Jian Jin (Assoc. Professor, CBMC Division, and Assoc. Director, Medicinal Chemistry in the CICBDD) is part of a multi-investigator team led by Drs. Bryan Roth (Professor, Dept. of Pharmacology and Division of CBMC) and Marc Caron (Professor, Duke University), which has received a five-year U19 grant from the National Institutes of Health. Dr. Jin (PI of Project 1) and his laboratory receive $1.15 million (direct cost) to create beta-arrestin-biased dopamine D2 receptor agonist clinical candidates for treatment of schizophrenia and other psychiatric disorders.
Collaborator Miriam Braunstein (Assoc. Prof., Microbiology and Immunology) and Bill Janzen (Dir. Assay Development and Compound Profiling) receive R01 grant from NIH for Developing High-Throughput Assays for M. Tuberculosis Tat Pathway Inhibitors.
Third Drug Discovery Contract awarded for Cancer Target
In August 2011 SAIC-Frederick, Inc., a prime contractor to the National Cancer Institute, extended UNC's contract for discovery of drugs to treat childhood leukemia based on milestones achieved during the first 12 months. The second contract, focused on brain tumors, is ongoing. In October SAIC awarded a third contract to UNC for a cancer target from NCI's NeXT program. Read more.
Stephen Frye, PhD, professor in the division of chemical biology and medicinal chemistry, and director of the UNC Center for Integrative Chemical Biology and Drug Discovery in the UNC Eshelman School of Pharmacy, is the lead principal investigator for the contracts. Frye is also a member of UNC Lineberger Comprehensive Cancer Center. The two centers are collaborating on all three projects.
Drug Discovery Contracts awarded for Two Cancer Targets (July 2010)
As part of a national effort to accelerate the identification and testing of new anticancer drugs, SAIC-Frederick, Inc., a prime contractor to the National Cancer Institute has awarded two contracts totaling $2.4 million to two teams of UNC scientists to initiate the discovery of drugs for the treatment of childhood leukemia and brain tumors.
Stephen Frye, PhD, professor of medicinal chemistry and director of the UNC Center for Integrative Chemical Biology and Drug Discovery in the UNC Eshelman School of Pharmacy, is principal investigator. Frye is also a member of UNC Lineberger Comprehensive Cancer Center. The two centers are collaborating on both projects. Read More
William Janzen receives small grant from National Institute on Drug Abuse for High-throughput Screening for the Discovery of Novel Scaffolds that Antagonize Methylated Histone Recognition. (1R03-DA030553)
CICBDD to collaborate on NIH Transformative R01 grant awarded to Dr. Mark Zylka, Asociate Professor of Cell and Molecular Biology, UNC School of Medicine.
This research will focus on harnessing particular enzymes found on the membrane of pain-sensing neurons and determining if these enzymes can be used alone or in combination to treat acute and chronic pain. In collaboration with a group headed by Stephen V. Frye, Ph.D. at the Eshelman School of Pharmacy, Zylka will use medicinal chemistry to synthesize “prodrugs,” pharmacologically inactive compounds that convert to the active form of the drug within the body.
Jian Jin to lead project funded by NIMH as supplement to U19 grant to collaborator Bryan Roth, PI (3U19MH082441-03S1) Functional Selectivity: A Novel Approach for CNS Drug Discovery
The overall objectives of this project are to create novel dopamine D2 ligands with unprecedented patterns of functional selectivity for elucidating the key signal transduction pathways essential for antipsychotic efficacy, and to discover novel, functionally selective antipsychotic drug candidates that are safer and more effective than existing antipsychotics.
Stephen Frye is awarded NIH Challenge Grant from the National Institute of General Medical Science for Discovery of Small Molecule MBT Domain Antagonists. (1RC1GM90732)
The primary objective of this research is to develop potent antagonists of methyl-lysine recognition by human and Drosophila MBT domain containing proteins in order to permit exploration of the biological consequences of blocking this recognition in cell based and in vivo models with relevance to normal and disease biology.
INNOVATION @ CAROLINA - A Chemical Biology Symposium - June 9, 2010
Introductory Presentation by Stephen Frye
Biochemical Modulation of Nociceptive Circuits by Mark J. Zylka
Rec-ing the DNA Repair Shop to Combat Antibiotic Resistance by Scott F. Singleton
Mer as a Target in Childhhood Leukemia by H. Shelton Earp